The fourth edition of Sweet Biopharma Day, which concluded successfully on October 9 at Espace Tonik in Sainte-Julie, once again showcased the vitality and collaborative spirit of Quebec's biopharmaceutical industry. Organized by adMare BioInnovations, AmorChem, BIOQuébec, CQDM, and the Fonds de solidarité FTQ, this invitation-only event allowed 16 innovative companies to present their projects to a prestigious audience, composed of influential industry representatives.

On October 4th, Biodextris, a member of BIOQuébec, inaugurated its brand-new facilities, made possible through an investment of nearly $25 million. These state-of-the-art infrastructures are designed to support the development of complex bioprocesses and biological products, further solidifying the company's role in life sciences innovation in Quebec.

Accelerate your career with the Life Sciences Entrepreneurship Development Program (PDESV). This 10-month hands-on program focuses on pharmaceutical product and medical device development. Led by industry experts, it equips participants with the essential skills to succeed in the life sciences sector.

Join this exceptional event that brings together internationally renowned experts, visionary start-ups, and leading researchers from Canada and Italy. This event is a unique opportunity to discover innovative projects and forge valuable connections with key players in the industry.

The PEACe 2025 conference (Protein Expression in Animal Cells), taking place in Montreal from September 14 to 18, 2025, offers an invaluable opportunity for life sciences companies to connect with world-renowned experts, influential researchers, and key decision-makers specializing in recombinant protein expression

Of the 7,000 known rare diseases, less than 10 per cent have an effective drug therapy. Of these, about 60 per cent are brought to Canada, where it can take up to an additional six years for approval versus the US or Europe.

MONTREAL, July 4, 2024 — Mila - Quebec Artificial Intelligence Institute is pleased to announce a partnership with Sorintellis, a Montreal-based AI company whose mission is to innovate pharmaceutical portfolio management using a data-driven approach and artificial intelligence (AI) technologies. 

MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics is delighted to announce the Quebec Government’s investment of $1.38 million via its Impulsion PME program, for which Investissement Québec acts as agent. With the addition of angel investors, this brings the total funding to $2.9 million needed for Neurenati to effectively advance NEU-001 toward clinical trials. NEU-001 is a proposed first-in-class therapy to treat Hirschsprung's disease, a rare gastrointestinal disease affecting approximately 1,300 newborns in North America each year.

Montreal, QC – The Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced today they have signed a memorandum of understanding (MOU) with Moderna Canada to support biomanufacturing training for employees at Moderna’s new vaccine manufacturing facility in Laval, Quebec.

MONTREAL, February 1, 2024 – ExCellThera Inc. (ExCellThera), a world leader in enhanced blood stem cell therapies, announced today a publication in the journal Blood that further elucidates the UM171 mechanism of action and highlights the potential for UM171 to result in the efficient expansion of stem cells with preserved function for therapeutic use.

MONTREAL, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today positive results from 50 patients in two multi-center Phase 2 trials for UM171 cell therapy conducted at transplant centers in the U.S., Canada and Europe, building on prior strong data from a Phase 1/2 trial and comparative registry studies (CIBMTR and EBMT).

(Charlottetown, PE –November 27, 2023) – Today, the Canadian Alliance for Skills and Training in Life Sciences (CASTL) announces the launch of its national biomanufacturing skills and training program – CASTL Elevate. CASTL Elevate is powered by Upskill Canada, and is part of the first wave of partnership programs that are taking an industry-informed approach to supporting workers in Canada’s fast-growing biomanufacturing sector.

Québec, Canada, November 28, 2023- Linearis Labs Inc (“Linearis”), an innovative company at the intersection of AI and biomarker analysis, announces today the inauguration of its new laboratory facilities at a site formerly occupied by Medicago Inc (“Medicago”). Following the announcement of the cessation of their operations after 26 years, Linearis acquired over 650 scientific instruments and hired some of their most seasoned specialized personnel in mass spectrometry, quality assurance, and laboratory management.

Vancouver (BC), Toronto (ON), and Montreal (QC) (November 21, 2023) - The adMare Institute released today the findings of its first white paper, considering the critical factors required to build a thriving life sciences industry and the essential role played by anchor companies.

The Ministère de l’Économie, de l’Innovation et de l’Énergie is issuing a call for projects to meet the innovation and commercialization needs of businesses and organizations, to help them become more competitive, ensure their growth and productivity, and integrate a culture of innovation into their practices, by creating a position of innovation and commercialization manager.

McGill University today announced it has signed agreements with ModernaTX, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to support two innovative research projects in the area of lipid nanoparticles (LNPs). LNPs are critical components in mRNA medicines such as vaccines, as they are the primary delivery method of mRNA strands to the target cells.

Montreal, Toronto, Vancouver (July 4, 2023) – The adMare Academy invites executives working in life sciences companies across Canada to apply to be part of Cohort VI of the Executive Institute.

Ottawa, May 31, 2023 – The Health Research Foundation (HRF) of Innovative Medicines Canada is pleased to announce that nominations are now open for the 2023 Diversity and Equity in Research Award. This new award recognizes a remarkable individual whose research demonstrates the highest quality of excellence and advances equitable participation in health research and access to health care in Canada, improving the well-being of all Canadians, particularly those facing inequities.

GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the “Arrangement”). The Arrangement was approved by BELLUS’ shareholders on 16 June 2023.

OTTAWA, ON, June 20, 2023 /CNW/ - The Patented Medicine Prices Review Board (PMPRB) launched a new 60-day Notice and Comment period today, encouraging stakeholders and interested members of the public to provide their input on new proposed Interim Guidance.

QUÉBEC CITY, June 13, 2023 /PRNewswire/ - Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment. The funds will primarily be used to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.

One of Aplantex’ technical partners, the Centre d’études des procédés chimiques du Québec (CEPROCQ) represented by Yacine Boumghar, Ph.D, has received a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to support the continued development of Aplantex’ innovative process to produce valuable molecules commonly used by the pharmaceutical, cosmetics, and agrifood industries.

BOSTON — The Manitoba government’s visionary new Life Sciences Strategy will power innovation and boost the province’s reputation as an internationally renowned hub for biosciences, Economic Development, Investment and Trade Minister Jeff Wharton announced today at the BIO International Convention in Boston.

MONTRÉAL, June 7, 2023 – Developing new generations of immunotherapies to treat currently incurable pediatric leukemia is the mission of Neomabs Biotechnologies, a new Montreal-based biotechnology company specializing in the discovery and development of innovative oncology therapies.

BOSTON, June 6, 2023 /PRNewswire/ - Calder Biosciences Inc., a molecular engineering and clinical manufacturing-stage biotechnology company pioneering its 3D-Vaxlockä platform technology to engineer and develop novel protein subunit vaccines, today announced a clinical supply agreement with Biodextris Inc.

Boston, Massachusetts – June 5, 2023 – CQDM is delighted, at BIO2023, in the presence of Minister Fitzgibbon, Quebec’s Minister of the Economy, Innovation and Energy (MEIE) to announce that Merck Canada, has renewed its commitment to CQDM with $3.0M in funding to support the development of innovative technologies in biopharmaceutical research.

MONTREAL and BOSTON, June 5, 2023 /CNW/ - Oncopole, Fonds de recherche du Québec - Santé (FRQS) cancer division, is proud to announce major investments that bolster its unique public-private partnership model dedicated to the fight against cancer. Building on its dynamism and ability to mobilize stakeholders in the life sciences community, Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada.

Montreal, Toronto, Vancouver (June 6, 2023) – adMare BioInnovations, a leader in the Canadian life sciences sector, is pleased to announce the launch of the adMare Institute, a new voice aimed at advancing the life sciences and related public policy in Canada. The announcement was made today at the prestigious BIO International Conference in Boston.

MONTREAL, June 5, 2023 /PRNewswire/ - Paraza Pharma is pleased to announce the appointment of Edward W. (Ted) Marple, A.B. (Harvard), MBA (Virginia) as Executive Vice-President, Development.

Grant recognizes CCfV's national leadership and Nova Scotian contribution to Canada's research capabilities, expected to attract top talent.

MISSISSAUGA, ON, May 31, 2023 /CNW/ - GSK announces a $1 million grant to strengthen the Canadian Center for Vaccinology (CCfV)'s position in the national infectious disease research landscape. The private funding will be a catalyst for growth of the Halifax-based centre, increasing employment opportunities and bolstering top-quality research and pandemic preparedness locally and nationally.